BioCryst Depreciation vs Stock Based Compensation Analysis

BCRX Stock

USD 6.31 0.13 2.02%

BioCryst Pharmaceuticals financial indicator trend analysis is way more than just evaluating BioCryst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioCryst Pharmaceuticals is a good investment. Please check the relationship between BioCryst Pharmaceuticals Depreciation and its Stock Based Compensation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Depreciation vs Stock Based Compensation

Depreciation vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioCryst Pharmaceuticals Depreciation account and Stock Based Compensation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between BioCryst Pharmaceuticals' Depreciation and Stock Based Compensation is 0.42. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of BioCryst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of BioCryst Pharmaceuticals' Depreciation and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of BioCryst Pharmaceuticals are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Depreciation i.e., BioCryst Pharmaceuticals' Depreciation and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.42

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Depreciation

Depreciation indicates how much of BioCryst Pharmaceuticals value has been used up. For tax purposes BioCryst Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, BioCryst Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324.9 K in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	327.6M	412.7M	428.8M	450.2M
Cost Of Revenue	7.3M	6.6M	6.3M	9.2M

Total Operating Expenses Cost Of Revenue

BioCryst Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Non Currrent Assets Other	Common Stock Total Equity	Short Term Investments	Common Stock	Other Liab	Current Deferred Revenue
Total Assets		0.93	0.9	0.87	-0.63	0.79	0.71	-0.94	0.91	0.75	0.06	0.99	0.95	0.94	0.15	0.52	0.95	0.81	1.0	-0.41	-0.31	0.93	0.64	0.93	-0.66	-0.3
Short Long Term Debt Total	0.93		0.88	0.81	-0.39	0.86	0.91	-0.92	0.79	0.51	-0.01	0.89	0.86	0.99	0.23	0.72	0.99	0.85	0.93	-0.42	-0.26	0.85	0.82	0.84	-0.54	-0.2
Other Current Liab	0.9	0.88		0.95	-0.55	0.9	0.77	-0.94	0.82	0.51	0.26	0.88	0.91	0.87	-0.08	0.58	0.9	0.87	0.88	-0.2	-0.22	0.9	0.76	0.9	-0.64	-0.34
Total Current Liabilities	0.87	0.81	0.95		-0.54	0.89	0.7	-0.95	0.87	0.49	0.19	0.86	0.94	0.81	-0.01	0.61	0.85	0.82	0.86	-0.02	-0.14	0.96	0.75	0.96	-0.72	-0.41
Total Stockholder Equity	-0.63	-0.39	-0.55	-0.54		-0.36	-0.07	0.58	-0.61	-0.8	-0.17	-0.68	-0.68	-0.41	0.36	0.27	-0.44	-0.53	-0.61	0.24	0.61	-0.63	0.0	-0.66	0.6	0.43
Property Plant And Equipment Net	0.79	0.86	0.9	0.89	-0.36		0.86	-0.9	0.7	0.28	0.12	0.75	0.83	0.84	0.08	0.72	0.87	0.94	0.79	-0.13	-0.22	0.84	0.89	0.83	-0.59	-0.25
Net Debt	0.71	0.91	0.77	0.7	-0.07	0.86		-0.79	0.53	0.11	0.02	0.64	0.67	0.88	0.28	0.87	0.87	0.81	0.71	-0.24	-0.14	0.67	0.95	0.65	-0.37	-0.13
Retained Earnings	-0.94	-0.92	-0.94	-0.95	0.58	-0.9	-0.79		-0.88	-0.57	-0.06	-0.92	-0.98	-0.92	-0.11	-0.63	-0.95	-0.88	-0.94	0.16	0.28	-0.97	-0.77	-0.97	0.67	0.43
Accounts Payable	0.91	0.79	0.82	0.87	-0.61	0.7	0.53	-0.88		0.77	-0.05	0.92	0.93	0.81	0.04	0.45	0.83	0.63	0.92	-0.24	-0.05	0.93	0.5	0.93	-0.64	-0.34
Cash	0.75	0.51	0.51	0.49	-0.8	0.28	0.11	-0.57	0.77		-0.07	0.81	0.68	0.55	-0.03	-0.1	0.56	0.38	0.76	-0.53	-0.35	0.63	-0.02	0.65	-0.52	-0.2
Non Current Assets Total	0.06	-0.01	0.26	0.19	-0.17	0.12	0.02	-0.06	-0.05	-0.07		0.08	0.05	-0.06	-0.13	-0.09	-0.03	0.16	-0.02	0.2	-0.19	0.0	0.06	0.01	0.0	-0.39
Cash And Short Term Investments	0.99	0.89	0.88	0.86	-0.68	0.75	0.64	-0.92	0.92	0.81	0.08		0.95	0.91	0.09	0.44	0.92	0.77	0.99	-0.43	-0.32	0.92	0.56	0.92	-0.68	-0.31
Common Stock Shares Outstanding	0.95	0.86	0.91	0.94	-0.68	0.83	0.67	-0.98	0.93	0.68	0.05	0.95		0.88	0.05	0.52	0.91	0.82	0.95	-0.18	-0.28	0.99	0.66	0.99	-0.72	-0.44
Non Current Liabilities Total	0.94	0.99	0.87	0.81	-0.41	0.84	0.88	-0.92	0.81	0.55	-0.06	0.91	0.88		0.26	0.71	1.0	0.84	0.95	-0.44	-0.26	0.86	0.79	0.85	-0.53	-0.2
Other Current Assets	0.15	0.23	-0.08	-0.01	0.36	0.08	0.28	-0.11	0.04	-0.03	-0.13	0.09	0.05	0.26		0.46	0.22	0.06	0.16	-0.08	-0.06	0.04	0.24	0.03	0.25	-0.04
Other Stockholder Equity	0.52	0.72	0.58	0.61	0.27	0.72	0.87	-0.63	0.45	-0.1	-0.09	0.44	0.52	0.71	0.46		0.71	0.53	0.53	0.03	0.25	0.55	0.92	0.52	-0.22	-0.1
Total Liab	0.95	0.99	0.9	0.85	-0.44	0.87	0.87	-0.95	0.83	0.56	-0.03	0.92	0.91	1.0	0.22	0.71		0.85	0.96	-0.39	-0.25	0.89	0.8	0.89	-0.57	-0.23
Property Plant And Equipment Gross	0.81	0.85	0.87	0.82	-0.53	0.94	0.81	-0.88	0.63	0.38	0.16	0.77	0.82	0.84	0.06	0.53	0.85		0.8	-0.28	-0.52	0.81	0.78	0.81	-0.59	-0.24
Total Current Assets	1.0	0.93	0.88	0.86	-0.61	0.79	0.71	-0.94	0.92	0.76	-0.02	0.99	0.95	0.95	0.16	0.53	0.96	0.8		-0.43	-0.3	0.93	0.63	0.93	-0.66	-0.27
Short Term Debt	-0.41	-0.42	-0.2	-0.02	0.24	-0.13	-0.24	0.16	-0.24	-0.53	0.2	-0.43	-0.18	-0.44	-0.08	0.03	-0.39	-0.28	-0.43		0.37	-0.12	-0.02	-0.13	0.13	-0.54
Non Currrent Assets Other	-0.31	-0.26	-0.22	-0.14	0.61	-0.22	-0.14	0.28	-0.05	-0.35	-0.19	-0.32	-0.28	-0.26	-0.06	0.25	-0.25	-0.52	-0.3	0.37		-0.22	-0.03	-0.25	0.26	0.12
Common Stock Total Equity	0.93	0.85	0.9	0.96	-0.63	0.84	0.67	-0.97	0.93	0.63	0.0	0.92	0.99	0.86	0.04	0.55	0.89	0.81	0.93	-0.12	-0.22		0.68	1.0	-0.76	-0.4
Short Term Investments	0.64	0.82	0.76	0.75	0.0	0.89	0.95	-0.77	0.5	-0.02	0.06	0.56	0.66	0.79	0.24	0.92	0.8	0.78	0.63	-0.02	-0.03	0.68		0.66	-0.44	-0.16
Common Stock	0.93	0.84	0.9	0.96	-0.66	0.83	0.65	-0.97	0.93	0.65	0.01	0.92	0.99	0.85	0.03	0.52	0.89	0.81	0.93	-0.13	-0.25	1.0	0.66		-0.77	-0.4
Other Liab	-0.66	-0.54	-0.64	-0.72	0.6	-0.59	-0.37	0.67	-0.64	-0.52	0.0	-0.68	-0.72	-0.53	0.25	-0.22	-0.57	-0.59	-0.66	0.13	0.26	-0.76	-0.44	-0.77		0.1
Current Deferred Revenue	-0.3	-0.2	-0.34	-0.41	0.43	-0.25	-0.13	0.43	-0.34	-0.2	-0.39	-0.31	-0.44	-0.2	-0.04	-0.1	-0.23	-0.24	-0.27	-0.54	0.12	-0.4	-0.16	-0.4	0.1

Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	175.3M	334.7M	588.2M	550M	517.0M	542.8M
Short Long Term Debt Total	84.7M	124.7M	593.2M	741.5M	848.7M	891.1M
Other Current Liab	36.3M	55.6M	72.7M	87.6M	102.9M	108.0M
Total Current Liabilities	92.3M	105.7M	103.7M	105.5M	150.0M	157.5M
Total Stockholder Equity	(840.6M)	(1.0B)	(1.2B)	(1.5B)	(455.5M)	(432.8M)
Property Plant And Equipment Net	7.3M	7.1M	8.7M	15.4M	21.0M	22.0M
Net Debt	(29.5M)	(147.4M)	88.8M	436.7M	736.3M	773.1M
Retained Earnings	(840.6M)	(1.0B)	(1.2B)	(1.5B)	(1.7B)	(1.6B)
Accounts Payable	14.0M	18.7M	27.8M	14.4M	20.9M	21.9M
Cash	114.2M	272.1M	504.4M	304.8M	112.4M	65.7M
Non Current Assets Total	10.9M	10.9M	22.0M	33.5M	21.0M	24.6M
Cash And Short Term Investments	136.2M	300.4M	514.4M	442.4M	390.8M	410.3M
Common Stock Shares Outstanding	115.6M	167.3M	179.1M	185.9M	192.2M	201.8M
Liabilities And Stockholders Equity	(703.6M)	(669.5M)	(512.4M)	(610.0M)	517.0M	542.8M
Non Current Liabilities Total	44.7M	248.3M	591.4M	739.1M	822.5M	863.6M
Other Current Assets	4.4M	5.5M	10.0M	12.6M	19.5M	20.5M
Other Stockholder Equity	(1.6M)	(1.8M)	(2.0M)	(1.9M)	1.2B	1.3B
Total Liab	137.0M	354.0M	695.1M	844.6M	972.5M	1.0B
Property Plant And Equipment Gross	7.3M	7.1M	8.7M	25.0M	19.1M	20.1M
Total Current Assets	164.3M	323.8M	566.1M	516.5M	496.0M	520.8M
Accumulated Other Comprehensive Income	39K	3K	177K	26K	1.3M	1.4M
Short Term Debt	40.0M	31.2M	1.8M	2.4M	26.2M	24.9M
Non Currrent Assets Other	3.6M	3.8M	6.5M	(33.5M)	12.0M	7.6M
Common Stock Total Equity	1.1M	1.5M	1.8M	1.8M	2.1M	2.2M
Short Term Investments	22.1M	28.2M	3.2M	119.5M	278.3M	292.3M
Common Stock	1.5M	1.8M	1.8M	1.9M	2.1M	2.2M
Current Deferred Revenue	2.1M	150K	1.4M	1.2M	1.1M	1.0M
Property Plant Equipment	7.3M	7.1M	15.2M	15.4M	17.7M	18.6M
Other Assets	2.0M	978K	588.2M	550M	632.5M	664.1M
Net Receivables	22.1M	8.6M	29.4M	50.6M	57.0M	59.8M
Inventory	1.6M	7.0M	15.8M	27.5M	28.7M	30.1M
Net Tangible Assets	82.9M	109.3M	(147.0M)	(294.6M)	(265.1M)	(251.9M)
Long Term Debt	41.3M	119.7M	585.5M	733.3M	811.3M	851.8M
Retained Earnings Total Equity	(732.0M)	(840.6M)	(1.0B)	(1.2B)	(1.1B)	(1.0B)
Long Term Debt Total	28.1M	41.3M	119.7M	136.1M	156.5M	164.3M
Capital Surpluse	780.4M	877.3M	1.0B	1.1B	1.3B	745.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

SGC	Superior Uniform Group
VLN	Valens
GNFT	Genfit

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioCryst Depreciation vs Stock Based Compensation Analysis

Depreciation vs Stock Based Compensation

Depreciation vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Depreciation

Stock Based Compensation

BioCryst Pharmaceuticals fundamental ratios Correlations

BioCryst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioCryst Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioCryst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.97	Retained Earnings
Total Liab	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Current Liabilities
Total Current Assets	- 0.94	Retained Earnings